| Literature DB >> 28877615 |
Michihide Tokuhira1, Shuntaro Saito1,2, Ayumi Okuyama3, Katsuya Suzuki2, Morihiro Higashi4, Shuji Momose4, Takayuki Shimizu5, Takehiko Mori5, Tomoe Anan-Nemoto1, Koichi Amano3, Shinichiro Okamoto5, Tsutomu Takeuchi2, Jun-Ichi Tamaru4, Masahiro Kizaki1.
Abstract
Although recent accumulative data reveal the clinicopathogenesis of regression in methotrexate-induced lymphoproliferative disorders (MTX-LPDs), the precise understanding including this category remains controversial. In this study, we analyzed 62 patients with MTX-LPD. Forty-three patients showed regression (Reg group), with high rates of Hodgkin lymphoma (HL) and LPD (90 and 88%, respectively). Among the 43 patients of the Reg group, 14 patients (33%) relapsed. The median duration before relapse in the Reg group was 10.6 months. Although the difference of OS between the Reg and Non-Reg groups was not significantly different, relapse-free patients in the Reg group had a superior overall survival (OS). MTX duration had a significant impact on Epstein-Barr virus (EBV) infection (p = .00131). Furthermore, EBV infection was significantly related to clinical manifestations, including spleen invasion, in the regression phenomenon. Some human leukocyte antigens (HLA) alleles might affect MTX-LPD development via EBV infection, although A*2402 and DRB1*0405 might be affected as fundamental factors.Entities:
Keywords: Methotrexate; autoimmune diseases; lymphoproliferative disorders; regression; rheumatoid arthritis
Mesh：
Substances：
Year: 2017 PMID： 28877615 DOI： 10.1080/10428194.2017.1369073
Source DB: PubMed Journal: Leuk Lymphoma ISSN： 1026-8022